Aardvark Therapeutics, Inc. (NASDAQ: AARD)

Sector: Healthcare Industry: Biotechnology CIK: 0001774857
P/B 1.34
P/E -3.36
P/S 0.00
Market Cap 163.67 Mn
ROIC (Qtr) -41.05
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 545,000.00
Debt/Equity (Qtr) 0.00

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 39.28M provide 91.57x coverage of short-term debt 429000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 133.23M provides 244.46x coverage of total debt 545000, indicating robust asset backing and low credit risk.
  • Short-term investments of 87.06M provide solid 14.85x coverage of other current liabilities 5.86M, indicating strong liquidity.
  • Tangible assets of 133.23M provide robust 22.72x coverage of other current liabilities 5.86M, indicating strong asset backing.
  • Cash reserves of 39.28M provide robust 3.66x coverage of current liabilities 10.74M, indicating strong short-term solvency.

Cons

  • Operating cash flow of (45.09M) barely covers its investment activities of (85.86M), with a coverage ratio of 0.53, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (85.86M) provide weak support for R&D spending of 42.70M, which is -2.01x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (45.09M) shows concerning coverage of stock compensation expenses of 2.54M, with a -17.75 ratio indicating potential earnings quality issues.
  • Free cash flow of (45.19M) provides weak coverage of capital expenditures of 101000, with a -447.43 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (48.77M) show weak coverage of depreciation charges of 436000, with a -111.86 ratio indicating high capital intensity and potential reinvestment needs.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 1.04 12.31
EV to Cash from Ops. -3.07 23.25
EV to Debt 253.79 738.44
EV to EBIT -2.84 -9.16
EV to EBITDA -2.61 6.95
EV to Free Cash Flow [EV/FCF] -3.06 21.90
EV to Market Cap 0.85 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 1.34 22.34
Price to Earnings [P/E] -3.36 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 1.94 -27.13
Cash and Equivalents Growth (1y) % -52.25 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -252.14 -46.93
EBITDA Growth (1y) % -244.25 -1.68
EBIT Growth (1y) % -252.14 -56.45
EBT Growth (1y) % -252.14 -12.70
EPS Growth (1y) % -23.21 -28.31
FCF Growth (1y) % -288.93 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 3.66 3.85
Current Ratio 12.04 7.27
Debt to Equity Ratio 0.00 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22